down arrow

INmune Bio, Inc.

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US45782T1051
USD
1.88
0.31 (19.75%)

Dec 04

NAS

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

1.691.92

52 Week

1.3811.64
Valuation
Technical
Day's Volume

CASH

731.5 k

Shareholding (Jun 2025)

FII

8.59%

Held by 32 FIIs

DII

82.22%

Held by 10 DIIs

Promoter

0.00%

How big is INmune Bio, Inc.?

22-Jun-2025

As of Jun 18, INmune Bio, Inc. has a market capitalization of 159.46 million and reported net sales of 0.05 million with a net profit of -40.80 million over the last four quarters. Shareholder's funds were 32.10 million, and total assets were 39.56 million as of Dec 24.

Market Cap: As of Jun 18, INmune Bio, Inc. has a market capitalization of 159.46 million, classified as a Micro Cap.<BR><BR>Recent Quarterly Performance: For the latest four quarters, the company reported net sales of 0.05 million and a net profit of -40.80 million.<BR><BR>Balance Sheet Snapshot: As of Dec 24, the company's shareholder's funds amounted to 32.10 million, while total assets were reported at 39.56 million.

Read More

What does INmune Bio, Inc. do?

22-Jun-2025

INmune Bio, Inc. is a clinical-stage pharmaceutical company focused on developing immunotherapy treatments for cancer. It has a market cap of approximately $159.46 million, with recent net sales of $0 million and a net loss of $10 million.

Overview: <BR>INmune Bio, Inc. is a clinical-stage pharmaceutical immunotherapy company focused on developing strategies for oncology by harnessing the innate immune system to treat cancer, operating within the Pharmaceuticals & Biotechnology industry and classified as a micro-cap company.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 0 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: -10 Million (Quarterly Results - Mar 2025) <BR>Market cap: USD 159.46 Million (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -0.65 <BR>Return on Equity: -137.49% <BR>Price to Book: 5.37<BR><BR>Contact Details: <BR>Address: 1200 Prospect St Ste 525, LA JOLLA CA: 92037-3608 <BR>Tel: 1 858 9643720 <BR>Website: http://www.inmunebio.com/

Read More

Is INmune Bio, Inc. technically bullish or bearish?

20-Sep-2025

As of July 10, 2025, INmune Bio, Inc. is in a bearish trend with multiple indicators confirming this stance, including bearish MACD and moving averages, and has significantly underperformed the S&P 500 with a year-to-date return of -57.82%.

As of 10 July 2025, the technical trend for INmune Bio, Inc. has changed from mildly bearish to bearish. The current technical stance is bearish with a strong indication from multiple indicators. The MACD is bearish on both weekly and monthly time frames, and the Bollinger Bands also reflect a bearish trend in both periods. Moving averages are bearish on the daily chart, and Dow Theory confirms a bearish stance on both weekly and monthly levels. The RSI shows a bullish signal on the weekly but no signal on the monthly, indicating mixed momentum. <BR><BR>In terms of performance, the stock has significantly underperformed compared to the S&P 500, with a year-to-date return of -57.82% versus the S&P 500's 12.22%, and a one-year return of -62.04% compared to 17.14% for the index. Overall, the bearish indicators suggest a challenging outlook for the stock.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
Icon
Unrated Stock - No Analysis Available
stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 48 Million ()

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-1.15

stock-summary
Return on Equity

-135.08%

stock-summary
Price to Book

1.67

Revenue and Profits:
Net Sales:
(Quarterly Results - Jun 2025)
Net Profit:
-24 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-4.57%
0%
-4.57%
6 Months
-74.14%
0%
-74.14%
1 Year
-63.64%
0%
-63.64%
2 Years
-80.44%
0%
-80.44%
3 Years
-72.81%
0%
-72.81%
4 Years
-83.24%
0%
-83.24%
5 Years
-78.01%
0%
-78.01%

INmune Bio, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News

Is INmune Bio, Inc. technically bullish or bearish?

As of 10 July 2025, the technical trend for INmune Bio, Inc. has changed from mildly bearish to bearish. The current technical stance is bearish with a strong indication from multiple indicators. The MACD is bearish on both weekly and monthly time frames, and the Bollinger Bands also reflect a bearish trend in both periods. Moving averages are bearish on the daily chart, and Dow Theory confirms a bearish stance on both weekly and monthly levels. The RSI shows a bullish signal on the weekly but no signal on the monthly, indicating mixed momentum. In terms of performance, the stock has significantly underperformed compared to the S&P 500, with a year-to-date return of -57.82% versus the S&P 500's 12.22%, and a one-year return of -62.04% compared to 17.14% for the index. Overall, the bearish indicators suggest a challenging outlook for the stock....

Read More
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
0.98%
EBIT Growth (5y)
-216.31%
EBIT to Interest (avg)
-25.68
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.65
Sales to Capital Employed (avg)
0.00
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
37.76%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
5.96
EV to EBIT
-3.80
EV to EBITDA
-3.80
EV to Capital Employed
15.04
EV to Sales
157.67
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-396.14%
ROE (Latest)
-137.49%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Bearish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Mildly Bullish
Bearish
Dow Theory
No Trend
Mildly Bearish
OBV
No Trend
Mildly Bearish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Jun 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 12 Schemes (9.2%)

Foreign Institutions

Held by 32 Foreign Institutions (8.59%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is -100.00% vs 0.00% in Mar 2025",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is -152.58% vs -5.43% in Mar 2025",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Mar'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.10",
          "chgp": "-100.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-8.10",
          "val2": "-9.90",
          "chgp": "18.18%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "-16.50",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-24.50",
          "val2": "-9.70",
          "chgp": "-152.58%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "-198,100.00%",
          "chgp": "19,810.00%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is -100.00% vs -50.00% in Dec 2023",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is -40.33% vs -9.89% in Dec 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.20",
          "chgp": "-100.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-42.60",
          "val2": "-29.70",
          "chgp": "-43.43%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-42.10",
          "val2": "-30.00",
          "chgp": "-40.33%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-3,045,357.10%",
          "val2": "-191,877.40%",
          "chgp": "-2,85,347.97%",
          "chgp_class": "negative"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQstock-summary
Jun'25
Mar'25
Change(%)
Net Sales
0.00
0.10
-100.00%
Operating Profit (PBDIT) excl Other Income
-8.10
-9.90
18.18%
Interest
0.00
0.00
Exceptional Items
-16.50
0.00
Consolidate Net Profit
-24.50
-9.70
-152.58%
Operating Profit Margin (Excl OI)
0.00%
-198,100.00%
19,810.00%
USD in Million.
stock-summary Compare with Peers
Direction Arrows
Net Sales

QoQ Growth in quarter ended Jun 2025 is -100.00% vs 0.00% in Mar 2025

Direction Arrows
Consolidated Net Profit

QoQ Growth in quarter ended Jun 2025 is -152.58% vs -5.43% in Mar 2025

All Quarterly Resultsstock-summary
Annual Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
0.00
0.20
-100.00%
Operating Profit (PBDIT) excl Other Income
-42.60
-29.70
-43.43%
Interest
0.00
0.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
-42.10
-30.00
-40.33%
Operating Profit Margin (Excl OI)
-3,045,357.10%
-191,877.40%
-2,85,347.97%
USD in Million.
stock-summary Compare with Peers
Direction Arrows
Net Sales

YoY Growth in year ended Dec 2024 is -100.00% vs -50.00% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is -40.33% vs -9.89% in Dec 2023

All Annual Resultsstock-summary
stock-summaryCompany CV
About INmune Bio, Inc. stock-summary
stock-summary
INmune Bio, Inc.
Pharmaceuticals & Biotechnology
Inmune Bio Inc. is a clinical-stage pharmaceutical immunotherapy company. The Company is focused on developing strategies for oncology that focus on re-engineering and harnessing the innate immune system to treat the patient’s cancer. The Company’s product candidates (INMB) target cells of the innate immune system that include natural killer cells (NK cells) and myeloid derived suppressor cells, (MDSC cells). The NK cell of the innate immune system has two primary functions, such as to kill virally infected cells and to kill cancer cells. Its INB03 is a protein biologic that has beneficial effects in patients with cancer. Its initial focus is on its ability to inhibit proliferation and function of myeloid-derived suppressor cells (MDSC).
Company Coordinates stock-summary
Company Details
1200 Prospect St Ste 525 , LA JOLLA CA : 92037-3608
stock-summary
Tel: 1 858 9643720
stock-summary
http://www.inmunebio.com/
stock-summary
Registrar Details
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."